India eyes space-based drug development via microgravity research
Synopsis
Key Takeaways
India is positioning itself to combine its formidable pharmaceutical manufacturing base with its expanding space programme, as scientists, biotechnology firms and startups explore how microgravity conditions could unlock the next generation of medicines. The convergence of two of India's greatest industrial strengths — its reputation as the pharmacy of the world and a rapidly maturing space infrastructure — is drawing serious attention from researchers and policymakers alike.
Key Discussions at Bengaluru Tech Summit
The possibility of manufacturing and testing drugs in space emerged as a focal point at the Bengaluru Tech Summit, which concluded on 19 November 2026. Researchers, policymakers and entrepreneurs gathered at the summit's space bio symposium to examine how India's future orbital infrastructure could support biotechnology research. The session reflected a growing consensus that space-based science is no longer purely the domain of astronomy and defence — it has clear commercial and medical applications.
The Science Behind Microgravity Pharmaceuticals
Scientists believe microgravity — the near-weightless condition experienced aboard orbiting spacecraft — offers distinct advantages for pharmaceutical research. On Earth, gravity interferes with the formation of protein crystals, causing inconsistencies that limit structural analysis. In microgravity, some protein crystals reportedly grow more uniformly, enabling researchers to study molecular structures in far greater detail. According to the report, such insights could improve drug formulations and potentially accelerate the development of new therapies. This scientific rationale has underpinned microgravity pharmaceutical experiments aboard the International Space Station (ISS) for decades, and India now seeks to participate in this research frontier at scale.
Biocon, Kiran Mazumdar-Shaw See Structural Opportunity
Leading biopharmaceutical company Biocon has signalled strong interest in the emerging field. The company's Executive Chairperson Kiran Mazumdar-Shaw said space technologies could help modify molecular structures, leading to the creation of new intellectual property, novel molecules and enhanced functionalities for drug development. Her remarks underscore that for India's pharma majors, space is not an abstract aspiration — it represents a potential source of proprietary science and competitive differentiation in global drug markets.
Bharatiya Antariksh Station and the Post-ISS Window
The timing of this push is deliberate. The International Space Station is expected to retire around 2030, prompting governments and private players worldwide to develop commercial orbital laboratories. India is working towards its proposed Bharatiya Antariksh Station, which is expected to be fully operational by 2035. Experts at the Bengaluru summit discussed how the planned station could eventually serve as an international hub for biotechnology and pharmaceutical research. Notably, some scientists argue that meaningful microgravity experiments can begin even before a permanent station becomes operational — through short-duration missions and commercial low-Earth orbit platforms — meaning India's pharma-space ambitions need not wait for 2035.
What This Means for India's Pharma and Space Sectors
India supplies a significant share of the world's generic medicines and vaccines, and microgravity research could add a high-value, IP-intensive layer to what has traditionally been a cost-driven manufacturing advantage. If translated into concrete research programmes, space-based drug development could attract global pharmaceutical partnerships, generate novel patent filings, and position India as a destination for orbital biotechnology — not just a source of affordable generics. The convergence is early-stage, but the institutional signals from both government and industry suggest momentum is building.